<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chloroprocaine (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chloroprocaine (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Chloroprocaine (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="139752" href="/d/html/139752.html" rel="external">see "Chloroprocaine (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="139773" href="/d/html/139773.html" rel="external">see "Chloroprocaine (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57261559"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Clorotekal;</li>
<li>Nesacaine;</li>
<li>Nesacaine-MPF</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F57262052"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Local Anesthetic</span></li></ul></div>
<div class="block dop drugH1Div" id="F57261599"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">Dose varies with procedure, desired depth, and duration of anesthesia, desired muscle relaxation, vascularity of tissues, physical condition, and age of patient. The smallest dose and concentration required to produce the desired effect should be used. Decrease dose in debilitated patients and patients with cardiac disease.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90f458d5-b4f3-459f-bad2-90564a9a2dec">Anesthesia, local injectable and peripheral nerve block</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anesthesia, local injectable and peripheral nerve block:</b> Children &gt;3 years and Adolescents: Maximum dose without epinephrine: 11 mg/kg; for infiltration, concentrations of 0.5% to 1% are recommended; for nerve block, concentrations of 1% to 1.5% are recommended</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F57261541"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution due to increased risk of adverse effects.</p></div>
<div class="block dohp drugH1Div" id="F57261539"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage should be reduced. Use with caution due to increased risk of adverse effects.</p></div>
<div class="block doa drugH1Div" id="F57261598"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="139752" href="/d/html/139752.html" rel="external">see "Chloroprocaine (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="806550a8-bbde-4773-bac6-49d476407ccf">Local anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Local anesthesia:</b>
<b>Note:</b> Use the smallest dose and concentration required to produce the desired result. Dosage varies with anesthetic procedure, the vascularity of the tissues, depth of anesthesia required, degree of muscle relaxation required, duration of anesthesia, and physical condition of the patient. Use reduced doses in debilitated patients and patients with cardiovascular disease. During epidural administration, a test dose (3 mL of 3% <b>or</b> 5 mL of 2%) is recommended prior to induction of complete block and all reinforcing doses with continuous catheter technique.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Clorotekal:</i> Subarachnoid block (spinal anesthesia): <b>Intrathecal:</b> 1%: 50 mg single dose (effective block to the T 10 level). <b>Note:</b> Other preservative- and antioxidant-free formulations (eg, Nesacaine-MPF) have also been used off-label (dosage range: 20 to 60 mg) for spinal anesthesia for short-duration ambulatory procedures; ensure that preservative-free products do not contain the antioxidant sodium bisulfite prior to administration (Gebhardt 2017; Hejtmanek 2011; Wesselink 2022).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Nesacaine, Nesacaine-MPF:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Maximum single dose (without epinephrine): 11 mg/kg; maximum total dose: 800 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum single dose (with epinephrine 1:200,000): 14 mg/kg; maximum total dose: 1,000 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">Caudal block (preservative free): 2% or 3%: 15 to 25 mL; may repeat at 40- to 60-minute intervals.</p>
<p style="text-indent:-2em;margin-left:4em;">Infiltration and peripheral nerve block:</p>
<p style="text-indent:-2em;margin-left:6em;">Brachial plexus: 2%: 30 to 40 mL; total dose 600 to 800 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Digital (without epinephrine): 1%: 3 to 4 mL; total dose: 30 to 40 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Infraorbital: 2%: 0.5 to 1 mL; total dose 10 to 20 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Mandibular: 2%: 2 to 3 mL; total dose 40 to 60 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Paracervical: 1%: 3 mL per each of four sites; total dose: up to 120 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Pudendal: 2%: 10 mL each side; total dose: 400 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">Lumbar epidural anesthesia, Cesarean delivery (preservative free): 3%: 15 to 20 mL total dose (includes test dose of 2 or 3 mL) (Bjornestad 2006; Feng 2012; Reschke 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Lumbar epidural anesthesia, nonpregnant (preservative free): 2% or 3%: 2 to 2.5 mL per segment; usual total volume: 15 to 25 mL; may repeat with doses that are 2 to 6 mL less than initial dose at 40- to 50-minute intervals.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F57261540"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Use with caution due to increased risk of adverse effects.</p></div>
<div class="block doha drugH1Div" id="F57261538"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer’s labeling; however, dosage should be reduced. Use with caution due to increased risk of adverse effects.</p></div>
<div class="block adr drugH1Div" id="F57261574"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac arrhythmia, cardiac insufficiency, hypertension, presyncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Fecal incontinence, oral hypoesthesia, oral paresthesia, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Groin pain, sexual disorder, urinary incontinence</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema, nonimmune anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia, anxiety, arachnoiditis, burning sensation, cauda equina syndrome, dizziness, drowsiness, dysesthesia, feeling hot, hypoesthesia, loss of consciousness, malaise, motor dysfunction, myoclonus, paresthesia, peripheral neuropathy, restlessness, seizure, speech disturbance, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, limb pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia, photophobia, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, dyspnea, respiratory depression</p></div>
<div class="block coi drugH1Div" id="F57261571"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to chloroprocaine, other para aminobenzoic acid (PABA) ester type anesthetics, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications described in the Clorotekal labeling (clinically, some may be applicable to other products): Contraindications specific to spinal anesthesia (eg, decompensated cardiac insufficiency, hypovolemic, shock, coagulopathy); IV regional anesthesia; serious cardiac conduction problems; local infection at the site of proposed lumbar puncture; sepsis.</p></div>
<div class="block war drugH1Div" id="F57261572"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Local anesthetics, at high systemic concentrations, are commonly associated with hypotension and bradycardia especially with inadvertent intravascular administration. Perform preventive measures (eg, limiting cumulative dose, use ultrasound or direct visualization for catheter placement). Careful and constant monitoring of the patient's cardiovascular vital signs should be done during and following each local anesthetic injection (Cox 2003; Dickerson 2014). In the event of cardiovascular collapse and/or severe CNS toxicity, treatment in accordance with the American Society of Regional Anesthesia and Pain Medicine’s Checklist for Treatment of Local Anesthetic Toxicity is recommended (Neal [ASRA 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Use extreme caution in patients with existing neurological disease. Seizures due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection. In the event of cardiovascular collapse and/or severe CNS toxicity, treatment in accordance with the American Society of Regional Anesthesia and Pain Medicine’s Checklist for Treatment of Local Anesthetic Toxicity is recommended (Neal [ASRA 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory effects: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest. Careful and constant monitoring of the patient's respiratory (adequacy of ventilation) vital signs should be done following each local anesthetic injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use extreme caution in patients with cardiovascular disease, including severe hypertension, hypotension, heart block, and severe cardiac decompensation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with extreme caution in patients with myasthenia gravis; may cause significant weakness (Haroutiunian 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Plasma cholinesterase disorders: Use with caution in patients with genetic deficiency of plasma cholinesterase.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with severe kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution in acutely ill; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in children; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epidural (thoracic, lumbar, or caudal) and intrathecal/spinal administration: <b>Do not use solutions containing preservatives. </b>Use extreme caution in patients with spinal deformities, neurologic disease, septicemia, and severe hypertension when used for thoracic, lumbar, and caudal epidural administration. With intrathecal/spinal administration, neurologic damage may occur after anesthesia (eg, paresthesia, loss of sensitivity, motor weakness, paralysis, cauda equina syndrome); symptoms may persist and may be permanent; carefully evaluate patients with underlying neuromuscular disorders while considering risk vs. benefit prior to treatment. Use with caution or avoid epidural or intrathecal/spinal administration in patients with bleeding disorders (congenital or acquired) and severe anemia (Horlocker 2010). Clorotekal (a product with specific FDA approval for intrathecal/spinal administration) is contraindicated in patients with serious cardiac conduction abnormalities, local infection at proposed lumbar puncture site, or sepsis; contraindications to intrathecal/spinal anesthesia should be taken into consideration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>
<div class="block foc drugH1Div" id="F57261611"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nesacaine: 1% (30 mL); 2% (30 mL) [contains disodium edta, methylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nesacaine-MPF: 2% (20 mL); 3% (20 mL) [methylparaben free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (20 mL); 3% (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intrathecal, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clorotekal: 1% (5 mL)</p></div>
<div class="block geq drugH1Div" id="F57261561"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F57261614"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Chloroprocaine HCl (PF) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $1.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3% (per mL): $1.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Clorotekal Intrathecal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $3.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nesacaine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $0.72</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $0.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nesacaine-MPF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $1.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3% (per mL): $1.34</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F57261536"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Administer locally as a single injection or continuously through an indwelling catheter. Avoid rapid injection. Do not use for subarachnoid administration. Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p></div>
<div class="block adm drugH1Div" id="F57261601"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Infiltration or peripheral nerve block:</b> Administer locally as a single injection or continuously through an indwelling catheter (peripheral nerve block). Avoid rapid injection. Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Epidural (thoracic, lumbar, or caudal) and subarachnoid block (spinal anesthesia): Do not use solutions containing preservatives. </b>Use a filter needle to draw up solution from ampule when using Clorotekal. <b>Clorotekal is intended for intrathecal administration only;</b> the manufacturer recommends against using for epidural administration. Use of Clorotekal via continuous spinal catheters is not recommended (safety has not been established). Do not puncture areas of the skin with signs of infection/inflammation. Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p></div>
<div class="block sts drugH1Div" id="F57261585"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F) in original container; protect from freezing. Protect from light. Discard Clorotekal and Nesacaine-MPF following single use. Solution in vials may become discolored with prolonged exposure to light; do not administer discolored solutions. Crystals of chloroprocaine may develop when exposed to low temperatures; when the vial is returned to room temperature, the crystals will redissolve with shaking; do not use solutions that contain undissolved matter. Do not heat before use; do not autoclave. Use immediately after initial puncture of vial or after ampule opening.</p></div>
<div class="block usep drugH1Div" id="F57261632"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Production of local anesthesia by local infiltration and peripheral nerve block techniques (Nesacaine, Nesacaine-MPF: FDA approved in children and adults); production of central nerve blocks including lumbar and caudal epidural blocks (Nesacaine-MPF: FDA approved in adults); production of local anesthesia by subarachnoid block (spinal anesthesia) (Clorotekal: FDA approved in adults).</p>
<p style="text-indent:0em;margin-top:2em;">Limitations of use: Nesacaine, Nesacaine-MPF: The manufacturer recommends against using either formulation (ie, with or without preservatives) for subarachnoid administration (ie, spinal anesthesia). Do not use chloroprocaine with preservatives (Nesacaine) for epidural or spinal anesthesia.</p></div>
<div class="block mst drugH1Div" id="F57261554"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Nesacaine may be confused with Neptazane</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F57261580"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57261577"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Chloroprocaine (Systemic) may enhance the hypertensive effect of Alpha-/Beta-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine.  Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics, but may be administered 20 minutes or more after lidocaine. Avoid all local anesthetics within 96 hours after administration of liposomal bupivacaine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Chloroprocaine (Systemic) may enhance the hypertensive effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylephrine (Systemic): Chloroprocaine (Systemic) may enhance the hypotensive effect of Phenylephrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonamide Antibiotics: Chloroprocaine (Systemic) may diminish the therapeutic effect of Sulfonamide Antibiotics.  Management: Avoid concurrent use of chloroprocaine and systemic sulfonamide-based antimicrobials whenever possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F57261569"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Chloroprocaine crosses the placenta (Kuhnert 1980).</p>
<p style="text-indent:0em;margin-top:2em;">Exposure to the fetus is expected to be limited due to the short maternal half-life but varies by route of administration (Nau 1985; Togioka 2022). Chloroprocaine may potentially cause varying degrees of maternal, fetal, and neonatal toxicity involving the CNS, peripheral vascular tone, and cardiac function depending on dose and administration technique.</p>
<p style="text-indent:0em;margin-top:2em;">Chloroprocaine is used in obstetric anesthesia (ACOG 2019; Novikova 2012; Reschke 2020). Use may be beneficial when a short onset of action is needed (Reschke 2020).</p></div>
<div class="block mopp drugH1Div" id="F57261633"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate, respiration, signs of CNS toxicity (lightheadedness, dizziness, tinnitus, restlessness, tremors, twitching, drowsiness, circumoral paresthesia, mental status).</p></div>
<div class="block pha drugH1Div" id="F57261586"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Chloroprocaine is an ester-type local anesthetic, which stabilizes the neuronal membranes and prevents initiation and transmission of nerve impulses thereby affecting local anesthetic actions. Chloroprocaine reversibly prevents generation and conduction of electrical impulses in neurons by decreasing the transient increase in permeability to sodium. The differential sensitivity generally depends on the size of the fiber; small fibers are more sensitive than larger fibers and require a longer period for recovery. Sensory pain fibers are usually blocked first, followed by fibers that transmit sensations of temperature, touch, and deep pressure. High concentrations block sympathetic somatic sensory and somatic motor fibers. The spread of anesthesia depends upon the distribution of the solution. This is primarily dependent on the volume of drug injected.</p></div>
<div class="block phk drugH1Div" id="F57261587"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 6 to 12 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration (patient, type of block, concentration, and method of anesthesia dependent): Up to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Depends upon route of administration; high concentrations found in highly perfused organs such as liver, lungs, heart, and brain</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly hydrolyzed by plasma enzymes to 2-chloro-4-aminobenzoic acid and beta-diethylaminoethanol (80% conjugated before elimination)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: In vitro, plasma: Neonates: 43 ± 2 seconds; Adults: 21 ± 2 seconds (males), 25 ± 1 second (females)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (minimal as unchanged drug in urine; metabolites: Chloro-aminobenzoic acid and beta-diethylaminoethanol primarily excreted unchanged)</p></div>
<div class="block phksp drugH1Div" id="F57261588"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Pharmacokinetic parameters can be significantly altered.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Pharmacokinetic parameters can be significantly altered.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58847710"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ampres</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ampres</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ampres | Chloroprocain HCI Sintetica | Ivracain</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ke pu nuo</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ampres</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ampres</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Clorotekal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ampres</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Decelex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Clorotekal</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ampres</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ampres</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ampres</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Chloroprocaine HCL | Clorotekal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ampres</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Decelex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-6614524">
<a name="6614524"></a>Abboud TK, Kim KC, Noueihed R, et al. Epidural bupivacaine, chloroprocaine, or lidocaine for cesarean section--maternal and neonatal effects. <i>Anesth Analg</i>. 1983;62(10):914-919.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/6614524/pubmed" id="6614524" target="_blank">6614524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24882123">
<a name="24882123"></a>Alley EA, Mulory MF. Neuraxial anesthesia for outpatients. <i>Anesthesiol Clin</i>. 2014;32(2):357-369. doi: 10.1016/j.anclin.2014.02.007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/24882123/pubmed" id="24882123" target="_blank">24882123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801474">
<a name="30801474"></a>American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 209: Obstetric Analgesia and Anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225. doi:10.1097/AOG.0000000000003132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/30801474/pubmed" id="30801474" target="_blank">30801474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16480471">
<a name="16480471"></a>Bjørnestad E, Iversen OL, Raeder J. Similar onset time of 2-chloroprocaine and lidocaine + epinephrine for epidural anesthesia for elective Cesarean section. <i>Acta Anaesthesiol Scand</i>. 2006;50(3):358-363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/16480471/pubmed" id="16480471" target="_blank">16480471</a>]</span>
<span class="doi">10.1111/j.1399-6576.2006.00937.x</span>
</div>
</li>
<li>
<div class="reference">
                  Chestnut DH, Wong CA, Tsen LC, Ngan Kee WD, Beilin Y, Mhyre JM. <i>Chestnut's Obstetric Anesthesia: Principles and Practice</i>. 5th ed. Philadelphia, PA: Elsevier Saunders; 2014.</div>
</li>
<li>
<div class="reference">
                  Clorotekal (chloroprocaine) [prescribing information]. Bethlehem, PA: B. Braun Medical Inc; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9010946">
<a name="9010946"></a>Coda B, Bausch S, Haas M, et al, “The Hypothesis That Antagonism of Fentanyl Analgesia by 2-Chloroprocaine Is Mediated by Direct Action on Opioid Receptors,” <i>Reg Anesth</i>, 1997, 22(1):43-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/9010946/pubmed" id="9010946" target="_blank">9010946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6691592">
<a name="6691592"></a>Corke BC, Carlson CG, and Dettbarn WD, “The Influence of 2-Chloroprocaine on the Subsequent Analgesic Potency of Bupivacaine,” <i>Anesthesiology</i>, 1984, 60(1):25-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/6691592/pubmed" id="6691592" target="_blank">6691592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12751552">
<a name="12751552"></a>Cox B, Durieux ME, Marcus MA. Toxicity of local anaesthetics. <i>Best Pract Res Clin Anaesthesiol</i>. 2003;17(1):111-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/12751552/pubmed" id="12751552" target="_blank">12751552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25028740">
<a name="25028740"></a>Dickerson DM, Apfelbaum JL. Local anesthetic systemic toxicity. <i>Aesthet Surg J</i>. 2014;34(7):1111-1119. doi: 10.1177/1090820X14543102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/25028740/pubmed" id="25028740" target="_blank">25028740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21263316">
<a name="21263316"></a>Dix SK, Rosner GF, Nayar M, et al, “Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,” <i>Crit Care Med</i>, 2011, 39(4):872-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/21263316/pubmed" id="21263316" target="_blank">21263316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22906283">
<a name="22906283"></a>Feng SW, Cao Y, Wang WG, Liu YS, Shen XF. Addition of adrenaline to chloroprocaine provides a moderate duration time for epidural anaesthesia in elective caesarean section. <i>J Int Med Res</i>. 2012;40(3):1099-1107. doi: 10.1177/147323001204000329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/22906283/pubmed" id="22906283" target="_blank">22906283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1243568">
<a name="1243568"></a>Freeman DW and Arnold NI, “Paracervical Block With Low Doses of Chloroprocaine: Fetal and Maternal Effects,” <i>JAMA</i>, 1975, 231(1):56-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/1243568/pubmed" id="1243568" target="_blank">1243568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27892594">
<a name="27892594"></a>Gebhardt V, Mueller-Hansen L, Schwarz A, Bussen D, Weiss C, Schmittner MD. Chloroprocaine 10 mg/ml for low-dose spinal anaesthesia in perianal surgery - a randomised dose finding study. <i>Acta Anaesthesiol Scand</i>. 2017;61(2):241-249. doi: 10.1111/aas.12839.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/27892594/pubmed" id="27892594" target="_blank">27892594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23320599">
<a name="23320599"></a>Goldblum E, Atchabahian A. The use of 2-chloroprocaine for spinal anaesthesia. <i>Acta Anaesthesiol Scand</i>. 2013;57(5):545-552. doi: 10.1111/aas.12071.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/23320599/pubmed" id="23320599" target="_blank">23320599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gropper.2019">
<a name="Gropper.2019"></a>Gropper M, Eriksson L, Fleisher L, eds. <i>Miller’s Anesthesia</i>. 9th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19670021">
<a name="19670021"></a>Haroutiunian S, Lecht S, Zur AA, et al The challenge of pain management in patients with myasthenia gravis. <i>J Pain Palliat Care Pharmacother</i>. 2009;23(3):242-260.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/19670021/pubmed" id="19670021" target="_blank">19670021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21288208">
<a name="21288208"></a>Hejtmanek MR, Pollock JE. Chloroprocaine for spinal anesthesia: a retrospective analysis. <i>Acta Anaesthesiol Scand</i>. 2011;55(3):267-272. doi: 10.1111/j.1399-6576.2010.02371.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/21288208/pubmed" id="21288208" target="_blank">21288208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20052816">
<a name="20052816"></a>Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). <i>Reg Anesth Pain Med</i>. 2010;35(1):64-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/20052816/pubmed" id="20052816" target="_blank">20052816</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Jankowsky EC, “Pharmacologic Aspects of Local Anesthetic Use,” <i>Anesth Clin North Am</i>, 1990, 8:1-25.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7386904">
<a name="7386904"></a>Kuhnert BR, Kuhnert PM, Prochaska AL, Gross TL. Plasma levels of 2-chloroprocaine in obstetric patients and their neonates after epidural anesthesia. <i>Anesthesiology</i>. 1980;53(1):21-25. doi:10.1097/00000542-198007000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/7386904/pubmed" id="7386904" target="_blank">7386904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32737881">
<a name="32737881"></a>Mitchell J, Jones W, Winkley E, Kinsella SM. Guideline on anaesthesia and sedation in breastfeeding women 2020: guideline from the Association of Anaesthetists. <i>Anaesthesia</i>. 2020;75(11):1482-1493. doi:10.1111/anae.15179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/32737881/pubmed" id="32737881" target="_blank">32737881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3891263">
<a name="3891263"></a>Nau H. Clinical pharmacokinetics in pregnancy and perinatology. I. Placental transfer and fetal side effects of local anaesthetic agents. <i>Dev Pharmacol Ther</i>. 1985;8(3):149-181. doi:10.1159/000457034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/3891263/pubmed" id="3891263" target="_blank">3891263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33148630">
<a name="33148630"></a>Neal JM, Neal EJ, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine local anesthetic systemic toxicity checklist: 2020 version. <i>Reg Anesth Pain Med</i>. 2021;46(1):81-82. doi:10.1136/rapm-2020-101986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/33148630/pubmed" id="33148630" target="_blank">33148630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nesacaine.1">
<a name="Nesacaine.1"></a>Nesacaine and Nesacaine-MPF (chloroprocaine) [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22513972">
<a name="22513972"></a>Novikova N, Cluver C. Local anaesthetic nerve block for pain management in labour. <i>Cochrane Database Syst Rev</i>. 2012;2012(4):CD009200. doi:10.1002/14651858.CD009200.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/22513972/pubmed" id="22513972" target="_blank">22513972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31867718">
<a name="31867718"></a>Reschke MM, Monks DT, Varaday SS, Ginosar Y, Palanisamy A, Singh PM. Choice of local anaesthetic for epidural caesarean section: a Bayesian network meta- analysis. <i>Anaesthesia</i>. 2020;75(5):674-682. doi:10.1111/anae.14966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/31867718/pubmed" id="31867718" target="_blank">31867718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35544759">
<a name="35544759"></a>Togioka BM, Zarnegarnia Y, Bleyle LA, et al. Pharmacokinetics and tolerability of intraperitoneal chloroprocaine after fetal extraction in women undergoing cesarean delivery. <i>Anesth Analg</i>. 2022. doi:10.1213/ANE.0000000000006064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/35544759/pubmed" id="35544759" target="_blank">35544759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31439640">
<a name="31439640"></a>Wesselink E, Hurk GJD, Vegt RV, et al. Chloroprocaine versus prilocaine for spinal anesthesia in ambulatory knee arthroscopy: a double-blind randomized trial. <i>Reg Anesth Pain Med</i>. 2019:rapm-2019-100673. doi:10.1136/rapm-2019-100673<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/31439640/pubmed" id="31439640" target="_blank">31439640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35027477">
<a name="35027477"></a>Wesselink EJ, Koopman SJ, Vegt RV, et al. ED90 of spinal 2-chloroprocaine 1% in ambulatory knee arthroscopy up to 45 min: a randomized biased-coin- up-and-down sequential allocation trial. <i>Reg Anesth Pain Med</i>. 2022;47(4):212-216. doi:10.1136/rapm-2021-103089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/35027477/pubmed" id="35027477" target="_blank">35027477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15673893">
<a name="15673893"></a>Yoos JR, Kopacz DJ. Spinal 2-chloroprocaine for surgery: an initial 10-month experience. <i>Anesth Analg</i>. 2005;100(2):553-558. doi: 10.1213/01.ANE.0000130397.38849.4A.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chloroprocaine-systemic-pediatric-drug-information/abstract-text/15673893/pubmed" id="15673893" target="_blank">15673893</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 139753 Version 16.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
